ES2829578T3 - Polimorfo cristalino de acetato de 15ß-hidroxi-osaterona - Google Patents

Polimorfo cristalino de acetato de 15ß-hidroxi-osaterona Download PDF

Info

Publication number
ES2829578T3
ES2829578T3 ES17796164T ES17796164T ES2829578T3 ES 2829578 T3 ES2829578 T3 ES 2829578T3 ES 17796164 T ES17796164 T ES 17796164T ES 17796164 T ES17796164 T ES 17796164T ES 2829578 T3 ES2829578 T3 ES 2829578T3
Authority
ES
Spain
Prior art keywords
polymorphic form
crystalline polymorphic
hydroxy
diffraction
crystalline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES17796164T
Other languages
English (en)
Spanish (es)
Inventor
Takayoshi Nakagawa
Hiroyuki Hayashi
Koichi Miyazaki
Shigeki Iwashita
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aska Pharmaceutical Co Ltd
Original Assignee
Aska Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aska Pharmaceutical Co Ltd filed Critical Aska Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ES2829578T3 publication Critical patent/ES2829578T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J73/00Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms
    • C07J73/001Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms by one hetero atom
    • C07J73/003Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms by one hetero atom by oxygen as hetero atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J73/00Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28Antiandrogens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/08Antiseborrheics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/14Drugs for dermatological disorders for baldness or alopecia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ES17796164T 2016-05-11 2017-05-10 Polimorfo cristalino de acetato de 15ß-hidroxi-osaterona Active ES2829578T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2016095382 2016-05-11
PCT/JP2017/017619 WO2017195804A1 (ja) 2016-05-11 2017-05-10 15β-ヒドロキシ-酢酸オサテロンの結晶多形

Publications (1)

Publication Number Publication Date
ES2829578T3 true ES2829578T3 (es) 2021-06-01

Family

ID=60267316

Family Applications (1)

Application Number Title Priority Date Filing Date
ES17796164T Active ES2829578T3 (es) 2016-05-11 2017-05-10 Polimorfo cristalino de acetato de 15ß-hidroxi-osaterona

Country Status (15)

Country Link
US (1) US10508130B2 (ru)
EP (1) EP3456729B1 (ru)
JP (2) JP7210278B2 (ru)
KR (1) KR102383617B1 (ru)
CN (1) CN109153701B (ru)
AU (1) AU2017264187B2 (ru)
BR (1) BR112018071950A2 (ru)
CA (1) CA3021179A1 (ru)
EA (1) EA034965B1 (ru)
ES (1) ES2829578T3 (ru)
MX (1) MX2018013786A (ru)
MY (1) MY195203A (ru)
PH (1) PH12018502365A1 (ru)
SG (1) SG11201809127PA (ru)
WO (1) WO2017195804A1 (ru)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2829578T3 (es) * 2016-05-11 2021-06-01 Aska Pharm Co Ltd Polimorfo cristalino de acetato de 15ß-hidroxi-osaterona
AU2020358203A1 (en) * 2019-10-02 2022-03-31 Aska Pharmaceutical Co., Ltd. Dysuria-alleviating agent
EP4265258A1 (en) * 2020-12-18 2023-10-25 ASKA Pharmaceutical Co., Ltd. Solid formulation

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3663668D1 (de) 1985-03-07 1989-07-06 Teikoku Hormone Mfg Co Ltd 2-oxa- or aza-pregnane compounds
JPS61204199A (ja) * 1985-03-07 1986-09-10 Teikoku Hormone Mfg Co Ltd 2−アザプレグナン化合物
JPS61204198A (ja) * 1985-03-07 1986-09-10 Teikoku Hormone Mfg Co Ltd 2−オキサプレグナン化合物
JPS62195398A (ja) * 1986-02-21 1987-08-28 Teikoku Hormone Mfg Co Ltd 黄体ホルモン剤
JP2591640B2 (ja) * 1988-02-04 1997-03-19 帝国臓器製薬株式会社 新規な2−オキサプレグナン化合物
JP2980992B2 (ja) * 1990-12-28 1999-11-22 帝国臓器製薬株式会社 6−ハロゲノ−2−オキサプレグナ−4,6−ジエン−3−オン化合物の製造方法
JP2591640Y2 (ja) 1993-05-13 1999-03-10 株式会社吉野工業所 液体収納袋
US7689305B2 (en) 2004-03-26 2010-03-30 Harman International Industries, Incorporated System for audio-related device communication
JP6192228B2 (ja) 2014-05-23 2017-09-06 本田技研工業株式会社 物体認識装置
ES2829578T3 (es) 2016-05-11 2021-06-01 Aska Pharm Co Ltd Polimorfo cristalino de acetato de 15ß-hidroxi-osaterona

Also Published As

Publication number Publication date
EA201892566A1 (ru) 2019-04-30
EP3456729A1 (en) 2019-03-20
SG11201809127PA (en) 2018-11-29
JP7241807B2 (ja) 2023-03-17
KR102383617B1 (ko) 2022-04-05
CA3021179A1 (en) 2017-11-16
AU2017264187A1 (en) 2018-11-15
WO2017195804A1 (ja) 2017-11-16
JPWO2017195804A1 (ja) 2019-03-07
BR112018071950A2 (pt) 2019-02-05
US20190127417A1 (en) 2019-05-02
PH12018502365A1 (en) 2019-09-09
JP2021121645A (ja) 2021-08-26
JP7210278B2 (ja) 2023-01-23
EA034965B1 (ru) 2020-04-13
KR20190004787A (ko) 2019-01-14
MX2018013786A (es) 2019-03-28
EP3456729A4 (en) 2019-05-22
CN109153701A (zh) 2019-01-04
US10508130B2 (en) 2019-12-17
CN109153701B (zh) 2021-02-02
MY195203A (en) 2023-01-11
EP3456729B1 (en) 2020-09-02
AU2017264187B2 (en) 2021-02-18

Similar Documents

Publication Publication Date Title
ES2253451T3 (es) Productos a base de hormona esteroide y sus procedimientos de fabricacion.
JP7241807B2 (ja) 15β-ヒドロキシ-酢酸オサテロンの結晶多形
ES2659938T3 (es) Ácido (5-fluoro-2-metil-3-quinolin-2-ilmetil-indol-1-il)-acético amorfo
ES2654927T3 (es) Formulaciones orales de derivados de pirrolidina
ES2673165T3 (es) Dispersión sólida amorfa para la utilización en el tratamiento del cáncer cerebral
BRPI0720277A2 (pt) Formulações e métodos de uso das mesmas
BR112017018533B1 (pt) Composição que compreende uma dispersão sólida de ospemifeno e seu método de preparação
US20200146977A1 (en) Pharmaceutical Composition for Oral Administration Comprising Enzalutamide
ES2874577T3 (es) Formas cristalinas de bilastina y procedimientos para su preparación
ES2377552T3 (es) Composiciones disueltas fácilmente y estables de candesartán cilexetilo preparadas con una granulación por vía húmeda
JP2011520928A (ja) キナゾリン誘導体を含む組成物、その調製方法及び使用
ES2291503T3 (es) Formas pseudopolimorficas de carvedilol.
JP5809367B2 (ja) レボノルゲストレルの結晶多形α及びその製造方法
BR112021008732A2 (pt) ingredientes farmacêuticos amorfos ativos compreendendo carbonato de magnésio mesoporoso substancialmente amorfo
ES2532110T3 (es) Cristal de un derivado de tienopirimidina
ES2346858T3 (es) Sustancia amorfa de un derivado triciclico de triazolobenzazepina.
JP5809368B2 (ja) レボノルゲストレルの結晶多形β及びその製造方法
ES2961011T3 (es) Compuesto farmacéutico, el método para su fabricación y uso como agente medicinal
ES2614516T3 (es) Método para preparar la forma A pura polimórfica de acetato de bazedoxifeno
EP2900683B1 (en) Crystalline polymorphic form of ulipristal acetate
ES2952033T3 (es) Sal y forma cristalina de un compuesto de furopirimidina y uso farmacéutico de estas
WO2014050105A1 (en) Amorphous ulipristal acetate
JP6433910B2 (ja) レボノルゲストレルの新規結晶混合物及びその製造方法